Identification of prokineticin-2 as potential pharmacodynamic biomarker for overcoming doxorubicin resistance in multicellular breast cancer spheroids.

Fiche publication

Date publication

septembre 2025

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr NEBIGIL-DESAUBRY Canan

Tous les auteurs :
Vincenzi M, Kremic A, Tscheiller NN, Hsu PY, Chan MWY, Lattanzi R, Nebigil CG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40976712

Résumé

Despite advances in immunotherapy, doxorubicin (Dox) chemotherapy is still the irreplaceable first-line therapy for solid tumours such as breast cancer. However, chemotherapy resistance is the major limiting factor, requiring the use of high doses of Dox to achieve the anti-tumour actions, often leading to severe side effects. Unravelling the mechanisms behind chemoresistance and identifying potential biomarkers for mitigating this resistance could enhance current treatment strategies and improve patient outcomes.